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Primary liver cancer, predominantly consisting of hepatocellular carcinoma (HCC), is one of the most common and aggressive
human malignancies worldwide. MicroRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression
post-transcriptionally. Emerging evidence indicates that miRNAs are often deregulated in HCC, and that some specific miRNAs are
associated with the clinicopathological features of HCC. Recent work demonstrates that miRNAs have essential roles in HCC
progression and directly contribute to cell proliferation, avoidance of apoptotic cell death, and metastasis of HCC by targeting a large
number of critical protein-coding genes. The discovery of the aberrantly expressed miRNAs and their corresponding targets has
opened a novel avenue to investigate the molecular mechanism of HCC progression and to develop potential therapeutics against
HCC. In this review, we summarise current knowledge about the roles and validated targets of miRNAs in liver cancer progression.
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Primary liver cancer mainly refers to hepatocellular carcinoma
(HCC), cholangiocarcinoma, and hepatic angiosarcoma. As the
third leading cause of death from cancer, HCC accounts for
85–90% of all primary liver cancers and ranks as the fifth most
prevalent malignancy worldwide (Farazi and DePinho, 2006).
Despite great advances in the treatment of the disease, relapse and
metastasis are frequently observed in the clinic, and the 5-year
survival rate remains quite low among patients with HCC. The
development and progression of HCC is typical of a multistage
process. The transformation begins in the liver tissue undergoing
chronic hepatitis or cirrhosis caused by external stimuli (hepatitis
B virus (HBV) or HCV infection, intake of aflatoxin B1, or alcohol
abuse), progresses through a series of hyperplastic and dysplastic
stages, and ultimately acquires the malignant phenotype
with intrahepatic metastasis and distal dissemination (El-Serag
and Rudolph, 2007). The progression is thought to involve the
deregulation of genes that are critical to cellular processes such as
cell cycle control, cell growth, apoptosis, and cell migration and
spreading. In the past decades, studies have focused on
investigating the genes and proteins underlying the development
and progression of HCC (Aravalli et al, 2008). Recently, an
increasing number of reports have described a new class of small
regulatory RNA molecules termed microRNAs (miRNAs) that are
implicated in HCC progression.
MicroRNAs are evolutionarily endogenous non-coding RNAs
that have been identified as post-transcriptional regulators of gene
expression (Bartel, 2004). The miRNAs mainly bind to the 30
untranslated regions (UTRs) of target mRNAs, resulting in mRNA
degradation or the blockade of mRNA translation. Computational
analysis indicates that 430% of protein-coding genes may be
directly modulated by miRNAs. Identification of miRNA targets is
becoming urgent for our understanding of miRNA function.
Increasing evidence shows that miRNAs have significant roles in
diverse biological processes (He and Hannon, 2004). Meanwhile,
deregulation of miRNAs has been observed in a wide range of
human diseases, including cancer (Calin and Croce, 2006). In
human cancer, miRNAs can function as oncogenes or tumour
suppressor genes during tumour development and progression
(Esquela-Kerscher and Slack, 2006).
Most recently miRNAs were found to be frequently deregulated
in HCC, and some specific miRNAs were found to be associated
with the clinicopathological features of HCC, such as metastasis,
recurrence, and prognosis (reviews by Braconi and Patel, 2008;
Ladeiro et al, 2008; Mott, 2009). Moreover, compelling evidence
demonstrates that miRNAs have important roles in HCC progres-
sion and directly contribute to the cell proliferation, avoidance of
apoptosis, and metastasis of HCC. Identifying the miRNAs and
their targets that are essential for HCC progression may provide
promising therapeutic opportunities. In this review, we discuss
recent advances in our knowledge of miRNAs and validated targets
in HCC progression (Table 1) and discuss potential future
perspectives.
DEREGULATED miRNAs AND CELL CYCLE
PROGRESSION OF HCC CELLS
It is well demonstrated that a defect in cell cycle control is an
essential step in the development and progression of human
cancer. A number of oncoproteins and tumour suppressors
involved in cell cycle regulation are often aberrant in HCC,
thereby promoting HCC cell proliferation. Recent reports showed
that some miRNAs can modulate the major proliferation pathways
through interacting with critical cell cycle regulators such as
cyclin–cyclin-dependent kinase enzyme (CDK) complexes, cell
cycle inhibitors of the Cip/Kip family, the phosphoinositide
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signalling cascade, and other cell growth regulatory genes.
Cyclins are a family of proteins that control the cell cycle
progression by activating CDKs. Both cyclins and CDKs, the
positive regulators of the cell cycle, are found to be targeted
by miRNAs in HCC. Cyclin D2 and cyclin E2 were validated as
direct targets of miR-26a, which exhibits reduced expression in
HCC (Kota et al, 2009). Expression of miR-26a induces HCC cell
cycle arrest associated with direct targeting of these two cyclins.
The mir-122, which accounts for 70% of the total liver miRNA
population, was found to be frequently downregulated in HCCs
and in all HCC-derived cell lines. Coulouarn et al (2009) identified
the liver-enriched transcription factors HNF1A, HNF3A, and
HNF3B as central regulatory molecules for loss of miR-122 in
HCC. The miR-122 can suppress HCC cell growth by directly
targeting cyclin G1 expression (Gramantieri et al, 2007). By
modulating cyclin G1, miR-122 influences p53 protein stability,
and transcriptional activity, thus decreasing the G2–M phase as
well as reducing the invasive capability of HCC-derived cells
(Fornari et al, 2009). Serum response factor (SRF) and insulin-like
growth factor 1 receptor (Igf1R), which both promote tumour-
igenesis, have also been validated as targets of miR-122 (Bai et al,
2009). The miR-195, one of the miR-15/16/195 family members,
was significantly reduced in HCC tissues and cell lines. The miR-
195 suppresses tumourigenicity and blocks the G1–S transition by
repressing Rb-E2F signalling through directly targeting multiple
molecules, including cyclin D1, CDK6, and E2F3 (Xu et al, 2009).
CDK6 was also shown to be targeted by miR-124, which was
silenced through CpG methylation in HCC and induced cell cycle
arrest at the G1–S checkpoint (Furuta et al, 2010). In addition,
miR-124 can mediate HCC cell growth arrest by directly targeting
vimentin, SET, and MYND domain containing 3, and IQ motif
containing GTPase activating protein 1 (Furuta et al, 2010).
On the other hand, some oncogenic miRNAs may exert their
functions through the inhibition of cyclin-dependent kinase
inhibitors (CDKIs), such as the members of Cip/Kip family.
The p21, a p53 target of the Cip/Kip family, is a direct target
of miR-106b and miR-93 (Ivanovska et al, 2008), which are
overexpressed in HCC and may have critical roles in cell
proliferation by regulating the G1-to-S cell cycle transition. The
p27, a second member of the Cip/Kip family with a relevant role as
a tumour suppressor in human cancer, is mostly controlled at the
post-transcriptional level. The miR-221 and miR-222 can function
as oncogenes in HCC by binding to target sites in the 30-UTR of
p27 (le Sage et al, 2007). Intriguingly, miR-221 and miR-222 have
been reported to directly interact with p57, another member of the
Cip/Kip family (Fornari et al, 2008). By controlling these two
CDKIs, miR-221 and miR-222 can promote HCC cell growth by
increasing the number of cells in the S-phase.
Phosphoinositide 3-kinase, a lipid kinase that integrates
different signals to balance survival and apoptosis, represents a
major signalling pathway for cell proliferation. The activation of
this pathway can increase the activity of AKT kinase, which can
phosphorylate mTOR, thereby promoting cell growth. The PI3K/
AKT pathway is controlled by the tumour suppressor lipid
phosphatase PTEN. Recently, mTOR was identified as a target of
miR-199a-3p which can block the G1–S transition and sensitise
HCC cells to doxorubicin challenge (Fornari et al, 2010). In
addition, the DNA damage-inducible transcript 4 (DDIT4), a
modulator of the mTOR pathway, was also found to be a bona fide
target of miR-221 and miR-222 (Pineau et al, 2010). Notably, PTEN
is a direct target of miR-21, miR-221, and miR-222, all of which are
Table 1 The aberrantly expressed miRNAs and validated targets in hepatocellular carcinoma
miRNA Expression Regulation Target genes Function References
let-7 Down ND c-Myc, Bcl-xL, COL1A2 Grow ( ), metastasis ( )J i et al (2010); Lan et al (2010); Shimizu et al
(2010)
miR-1 Down Methylation c-Met, FoxP1, HDAC4 Grow ( ), metastasis ( ) Datta et al (2008)
mir-17-5p Up ND ND Grow (+), metastasis (+) Yang et al (2010a)
miR-101 Down ND Mcl-1, FOS Grow ( ), apoptosis (+),
metastasis ( )
Su et al (2009); Li et al (2009b)
miR-106b-25 Up ND p21, Bim Grow (+), apoptosis ( )L i et al (2009c)
miR-122 Down HNF1A,
HNF3A,
HNF3B
Cyclin G1, SRF, Igf1R, Bcl-w,
ADAM10, ADAM17
Grow ( ), metastasis ( ),
apoptosis (+)
Gramantieri et al (2007); Lin et al (2008); Bai
et al (2009); Coulouarn et al (2009); Fornari
et al (2009); Tsai et al (2009); Zhang et al
(2009a); Ma et al (2010)
miR-124 Down Methylation CDK6, VIM, SMYD3, IQGAP1 Grow ( ), metastasis ( )
a Furuta et al (2010)
miR-143 Up NF-kB FNDC3B Metastasis (+) Zhang et al (2009b)
miR-151 Up Gain on 8q24.3 RhoGDIA Metastasis (+) Ding et al (2010)
miR-181b Up TGF-b TIMP3 Metastasis (+) Wang et al (2010)
miR-18a Up ND ERa Grow (+) Liu et al (2009)
miR-195 Down ND cyclin D1, CDK6, E2F3 Grow ( )X u et al (2009)
miR-199a-3p Down ND mTOR, c-Met Grow ( ), metastasis ( ) Fornari et al (2010)
miR-203 Down Methylation ABCE1 Apoptosis (+) Furuta et al (2010)
miR-21 Up ND PTEN Grow (+), metastasis (+),
apoptosis ( )
Meng et al (2007)
miR-221/222 Up c-Jun p27, p57, DDIT4, PTEN,
Bmf, TIMP3, PPP2R2A
Grow (+), metastasis (+),
apoptosis ( )
le Sage et al (2007); Fornari et al (2008);
Garofalo et al (2009); Gramantieri et al (2009);
Pineau et al (2010); Wong et al (2010)
miR-223 Down ND Stathmin 1 Grow ( ) Wong et al (2008)
miR-224 Up ND API-5 Grow (+), apoptosis (+) Wang et al (2008)
miR-23b Down ND uPA, c-Met Metastasis ( ) Salvi et al (2009)
miR-26a Down ND Cyclin D2, Cyclin E2 Grow ( ) Kota et al (2009)
miR-29 Down ND Bcl-2, Mcl-1 Apoptosis (+) Xiong et al (2010)
miR-30d Up ND Gai2 Metastasis (+) Yao et al (2010)
miR-34a Down ND c-Met Metastasis ( )L i et al (2009a)
miR-375 Down ND YAP Grow ( ), metastasis ( ) Liu et al (2010)
miR-602 Up ND RASSF1A Grow (+), apoptosis ( ) Yang et al (2010b)
Abbreviations: ( )¼inhibition; (+)¼promotion; down¼downregulated; ND¼not determined; up¼upregulated.
aHypothesis.
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2009). Thus, PTEN could be repressed by these miRNAs, which
results in HCC cell survival through PI3K/AKT pathway activation.
In addition, the deregulated miRNAs can affect HCC cell
proliferation through other important cell cycle regulators. Let-7g
inhibits the proliferation of HCC cells by downregulation of c-Myc
and upregulation of p16(INK4A) (Lan et al, 2010). The miR-1 that is
methylated in HCC suppresses tumour cell growth by downregulating
its oncogenic targets c-Met, FoxP1, and HDAC4 (Datta et al, 2008).
Stathmin1, a functional target of miR-223 that is downregulated
in HCC, is a key microtubule regulatory protein that controls
microtubule dynamics, cellular proliferation, and the S-phase of the
cell cycle (Wong et al, 2008). The miR-375 inhibits the proliferation
and invasion of HCC cells by targeting Hippo-signalling effector
YAP (Liu et al, 2010). The miR-18a is preferentially increased in
female HCC and stimulates the proliferation of HCC cells through
downregulating the ESR1 gene, which encodes ERa, thus potentially
blocking the protective effects of oestrogen and promoting the
development of HCC in females (Liu et al, 2009).
DEREGULATED miRNAs AND APOPTOSIS
OF HCC CELLS
Apoptosis is a major barrier that must be circumvented during
malignant transformation and tumour progression. Tumour cells
evolve to evade apoptosis so that they can escape from the
surveillance system and survive in the tumour environment. Many
of the signals that elicit apoptosis converge on the mitochondria,
which respond to proapoptotic signals by releasing cytochrome c,
a potent catalyst of apoptosis. The Bcl-2 family of proteins, whose
members have either proapoptotic (Bim, Bmf, Bax, Bak, Bid)
or antiapoptotic (Bcl-2, Bcl-W, Bcl-XL, Mcl-1) function, have
important roles in governing mitochondrial death signalling. A
growing body of evidence shows that miRNAs can help cancer cells
to evade apoptosis by directly targeting the Bcl-2 family genes in
HCC. The cellular mRNA and protein levels of Bcl-w were
repressed by miR-122, which subsequently reduced cell viability
and caspase-3 activation (Lin et al, 2008). The let-7 family of
miRNAs inhibits Bcl-xL expression and potentiates sorafenib-
induced apoptosis (Shimizu et al, 2010). The miR-101 may exert
its proapoptotic function by targeting Mcl-1 (Su et al, 2009).
Intriguingly, both Mcl-1 and Bcl-2 were direct targets of miR-29,
and the mitochondrial pathway was activated in miR-29-promoted
apoptosis (Xiong et al, 2010). Enhanced miR-29 expression can
sensitise HCC cells to various apoptotic signals and suppress the
tumourigenicity of HCC cells. All of these miRNAs are frequently
downregulated in HCC, thus making HCC cells more resistant to
apoptosis by upregulating the expression of antiapoptotic genes.
On the other hand, Bmf, a proapoptotic BH3-only protein, is a
target of miR-221 in hepatic carcinogenesis (Gramantieri et al,
2009). The miR-25 exerts an antiapoptotic effect by targeting and
inhibiting Bim (Li et al, 2009c).
MicroRNAs can also regulate apoptotic cell death by targeting
other apoptosis related genes. The miR-224, which is upregulated
in HCC, sensitises cells to apoptosis by inhibiting apoptosis
inhibitor-5 and increases cell proliferation (Wang et al, 2008). The
miR-602 has an antiapoptotic role in HBV-related HCCs by
inhibiting RASSF1A (Yang et al, 2010b). Restoration of miR-203 in
HCC cell lines induces apoptosis by targeting ABCE1 (Furuta et al,
2010).
DEREGULATED miRNAs AND THE INVASION
AND METASTASIS OF HCC CELLS
Invasion and metastasis, two of the most critical hallmarks of
cancer, are the leading lethal factors for malignant cancer in
general and HCC in particular. The long-term survival of HCC
patients after curative resection is still plagued by the major
obstacle of a high recurrence rate, which is mainly because of the
spread of intrahepatic metastasis. Identification of metastatic
factors and understanding the mechanisms underlying metastasis
are important for the treatment of HCC. An increasing number of
pro-metastatic miRNAs and anti-metastatic miRNAs are identified
as upstream regulators of metastasis related genes and have a
fundamental role in the invasion and metastasis of HCC cells.
Pro-metastatic miRNAs and their targets in HCC
Meng et al (2007) first reported that aberrant expression of miR-21
can not only contribute to HCC growth, but also mediate HCC
cell invasion by directly targeting PTEN. The miR-21 can alter
focal adhesion kinase (FAK) phosphorylation and the expression
of matrix metalloproteases MMP2 and MMP9, both downstream
mediators of PTEN involved in cell migration and invasion.
Recently, PTEN was also found to be the direct target of miR-221
and miR-222, which induce TRAIL resistance and enhance HCC
cell migration (Garofalo et al, 2009). Besides PTEN, miR-221
and miR-222 also directly regulate the expression of the protein
phosphatase 2A subunit B (PPP2R2A) and TIMP3 tumour
suppressors, thus activating the AKT pathway and metallopepti-
dases to promote HCC cell invasion and metastasis (Garofalo et al,
2009; Wong et al, 2010). Interestingly, TIMP3 was also a functional
target of miR-181b (Wang et al, 2010).The miR-181b is induced by
TGF-b, and enhances MMP2 and MMP9 activity by modulating
TIMP3 levels, thus promoting migration and invasion of HCC
cells. This TGF-b/miR-181/TIMP3 axis might serve as an
important complement to the TGF-b-mediated metastasis network.
One report (Zhang et al, 2009b) also showed a novel miRNA (miR-
143) mediated by nuclear factor kB (NF-kB) that promoted the
metastasis of HBV-related HCC (HBV–HCC). Upregulation of
miR-143 expression by NF-kB in HBV–HCC promotes invasion
and metastasis by repression of fibronectin type III domain
containing 3B. Additionally, miR-17-5p, which is upregulated in
HCC, promotes HCC cell invasion dependent on the activation of
p38 mitogen-activated protein kinase and increased phosphoryla-
tion of heat shock protein 27 (Yang et al, 2010a).
Recently, miR-30d and miR-151, two frequently amplified
miRNAs on chromosome 8q24, were found to be involved in
HCC invasion and metastasis (Ding et al, 2010; Yao et al, 2010).
The chromosomal region 8q24 is a common recurrent amplifica-
tion region and is related to the metastatic properties in HCC. The
miR-30d is frequently upregulated in HCC and its expression is
associated with intrahepatic metastasis. High expression of miR-
30d can enhance intrahepatic and distal pulmonary metastasis of
HCC cells by repressing the direct and functional target G-ai2. The
miR-151, which is often co-expressed with the host gene FAK,
increases HCC cell migration and invasion by directly targeting
RhoGDIA, a candidate metastasis suppressor in HCC, thus
resulting in the activation of Rac1, Cdc42 and Rho GTPases.
Moreover, miR-151 can function synergistically with FAK to
enhance HCC cell motility and spreading.
Anti-metastatic miRNAs and their targets in HCC
The miR-122 is significantly downregulated in liver cancers and
suppresses HCC intrahepatic metastasis by regulation of a
disintegrin and metalloprotease family proteins ADAM10 and
ADAM17 (Bai et al, 2009; Tsai et al, 2009). let-7g was also shown to
be present at significantly lower levels in metastatic HCCs and may
suppress HCC metastasis by targeting type I collagen a2 (Ji et al,
2010). The hepatocyte growth factor (HGF)/c-Met signalling
cascade is considered to be widely involved in the tumour
metastatic process. The HGF interacts with c-Met receptor tyrosine
kinase and leads to invasive growth by stimulating cell motility,
invasion, and protection from apoptosis. The c-Met is frequently
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outcomes of many tumours including HCC. The exact mechanism
of upregulation of this gene in cancer remains poorly understood.
Recently, the c-Met oncogene has been shown to be regulated by
miR-1, miR-34a, miR-23b, and miR-199a-3p, all of which are
downregulated in HCC. Silencing of miR-1 can not only inhibit
HCC growth, but also mediate HCC cell invasion by down-
regulating c-Met (Datta et al, 2008). The miR-34a decreased c-Met-
induced phosphorylation of extracellular signal-regulated kinases
1 and 2, and inhibited tumour cell migration and invasion (Li et al,
2009a). The miR-23b decreased the migration and proliferation
abilities of HCC cells by downregulating c-Met and urokinase-type
plasminogen activator, the latter of which is a critical functional
downstream target of HGF/c-Met signalling (Salvi et al, 2009).
The miR-199a-3p, decreased in HCC, induced G1-phase cell
cycle arrest, and reduced invasive capability by targeting c-Met
and mTOR (Fornari et al, 2010). The miR-101, a miRNA repressed
in HCC, inhibits the expression of the FOS oncogene post-
transcriptionally, thereby reducing HGF-induced cell invasion and
migration (Li et al, 2009b).
CONCLUSION AND FUTURE PERSPECTIVES
Current findings demonstrate that many miRNAs are differentially
expressed in HCC, and have essential roles in liver cancer
progression through directly targeting a large number of critical
genes in HCC cells. Similar to protein coding genes, miRNAs are
transcribed by RNA polymerase II and may be regulated at
transcriptional levels. As shown in Figure 1A, miR-181 is regulated
by TGF-b signalling; miR-143 is regulated by NF-kB; miR-221 and
miR-222 are regulated by HGF/c-Met signalling through the c-Jun
transcription factor. Genetic and epigenetic aberrations may also
contribute to the deregulation of miRNAs in HCC. For example,
miR-1, miR-124, and miR-203 are silenced because of CpG
methylation, and miR-151 is highly expressed in HCC because of
the gain of chromosome 8q24. However, current knowledge about
the molecular mechanisms of the control of expression for most of
these deregulated miRNAs remains limited. Furthermore, the
linkages between the aberrant miRNAs and the aetiology of HCC
need to be further explored.
Although computational analysis indicates that one miRNA may
directly modulate hundreds of mRNAs, such regulation has not
been convincingly demonstrated experimentally. As shown in
Figure 1B, some miRNAs have been shown to target multiple genes
involved in HCC progression. For example, miR-221 and miR-222
can target p27, p57, Bmf, PTEN, TIMP3, DDIT4, and PPP2R2A; and
miR-122 can target cyclin G1, ADAM10, ADAM17, SRF, Igf1R, and
Bcl-w. As these target genes are involved in different cellular
processes, individual miRNAs thus have multi-faceted roles in
HCC progression. Conversely, a single gene may be regulated by
multiple miRNAs. As shown in Figure 1B, c-Met, PTEN, TIMP3,
Mcl-1, and CDK6 are found to be regulated by at least two miRNAs
in HCC. Therefore, it is important to note that the alteration of the
expression of a single miRNA may not be sufficient to influence a
specific target gene. From these observations, we can deduce that
the deregulated miRNAs and their target mRNAs construct a
complex interacting network controlling HCC progression.
Technological advances indicate that the use of miRNAs or
antagomir as therapeutics is feasible and safe. The discovery of
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Figure 1 The interacting network of the aberrant miRNAs and their target genes in liver cancer progression. (A) The molecular mechanisms of the
control of expression for some of the deregulated miRNAs. (B) The deregulated miRNAs and their target genes construct a complex interacting network to
control HCC progression, and directly contribute to cell proliferation, avoidance of apoptotic cell death, and metastasis of HCC.
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contributed to the development of miRNA-based therapeutics for
HCC. Recently, Kota et al (2009) found that systemic administra-
tion of miR-26a in a mouse model results in inhibition of HCC
cell proliferation, induction of tumour-specific apoptosis, and
dramatic protection from disease progression without toxicity.
This study provided an effective and promising strategy for
future miRNA replacement therapies for the treatment of HCC.
Note that these already identified deregulated miRNAs are
aberrantly expressed and exert their functions only in a portion
of HCC cases. One of the most important issues to be addressed is
whether these deregulated miRNAs can be used to subtype HCC
populations, categorising HCC cases into several subgroups based
on their miRNA signatures, which will deepen our understanding
of the underlying molecular mechanisms of hepatic carcinogenesis,
and will facilitate the development of personalised miRNA-based
therapeutics against HCC.
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